1. Home
  2. JQC vs DRTS Comparison

JQC vs DRTS Comparison

Compare JQC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$4.78

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$8.11

Market Cap

641.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
DRTS
Founded
2003
2015
Country
United States
Israel
Employees
N/A
121
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
641.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JQC
DRTS
Price
$4.78
$8.11
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
801.1K
242.2K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$699.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$2.50
52 Week High
$5.58
$8.60

Technical Indicators

Market Signals
Indicator
JQC
DRTS
Relative Strength Index (RSI) 44.84 63.17
Support Level $4.69 $6.37
Resistance Level $4.89 $8.60
Average True Range (ATR) 0.05 0.41
MACD -0.00 0.06
Stochastic Oscillator 22.58 79.31

Price Performance

Historical Comparison
JQC
DRTS

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: